| Date | Title | Description | |
|---|---|---|---|
| 26 Jul 2023 | On P&L | The Company releases the press release related to the first half 2023 financial results | Download |
| 26 Jul 2023 | On P&L | The Company releases the first half 2023 financial results presentation | Download |
| 26 Jul 2023 | On buy-back programmes | The Company reports the commencement, effective as of today, 26 July 2023, of a share buyback program. | Download |
| 10 May 2023 | On P&L | The Company releases the first quarter 2023 financial results presentation | Download |
| 10 May 2023 | On P&L | The Company releases the press release related to the first quarter 2023 financial results | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 07 Oct 2021 | Liquidity and counterparty agreements | Download | |
| 04 Oct 2021 | Liquidity and counterparty agreements | Download | |
| 01 Sep 2021 | On business and financial situation | ROVI informs about the joint statement from Moderna and Takeda on the investigation of suspended lots of the vaccine | Download |
| 28 Jul 2021 | On business and financial situation | The company releases the press release related to first half 2021 financial results | Download |
| 28 Jul 2021 | On business and financial situation | ROVI releases the first half 2021 results presentation | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 16 Feb 2017 | Información sobre resultados (2) | ROVI releases the press release related to the full year 2016 results | Download |
| 16 Feb 2017 | Información sobre resultados | ROVI releases the presentation related to the full year 2016 results | Download |
| 16 Feb 2017 | Informe Anual de Gobierno Corporativo | ROVI releases the 2016 Annual Corporate Governance Report | Download |
| 10 Jan 2017 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted in the fourth quarter of 2016 | Download |
| 22 Nov 2016 | Acuerdos estratégicos con terceros | ROVI announces the marketing agreement of Neparvis in Spain | Download |